Weeks Before Oral Args, Mylan Drops AstraZeneca IP Appeal
At the parties' request, the Federal Circuit on Thursday dismissed Mylan Pharmaceuticals Inc.'s bid to upend a lower court decision upholding the validity of AstraZeneca AB's patent on two diabetes drugs,...To view the full article, register now.
Already a subscriber? Click here to view full article